Answers are grounded in this paper and cite their sources.
Randomised trial assesses dose reduction of methotrexate or TNF inhibitor timing on disease control in arthritis patients, suggesting feasible tapering strategies.
Treatment tapering may not be feasible in patients with low disease activity, whereas both extending the TNF inhibitor interval and reducing the methotrexate dose may be reasonable options for patients in remission.
No takes yet. Share an insight, caveat, or question.
Imai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: